Top

Published in:

01-12-2011 | Research

Lymphatic Differentiation in Classic Kaposi’s Sarcoma: Patterns of D2-40 Immunoexpression in the Course of Tumor Progression

Authors: Nilufer Onak Kandemir, Figen Barut, Banu Dogan Gun, Sevinc Hallac Keser, Nimet Karadayi, Mustafa Gun, Sukru Oguz Ozdamar

Published in: Pathology & Oncology Research | Issue 4/2011

Abstract

The recent development of lymphatic endothelium-specific immuno-indicators has given rise to research on the histogenesis of Kaposi sarcoma (KS), specifically focusing on its lymphatic root and differentiation. D2-40 is a new lymphatic marker that recognizes podoplanin and is easily applied to formalin-fixed paraffin-embedded human tissues. This study examined D2-40 immunoexpression in 178 classical KS lesions using immunohistochemical methods. D2-40 immunoexpression was also examined in 63 non-KS soft tissue lesions to test the reliability of D2-40 monoclonal antibody in the pathological diagnosis of KS. D2-40 immunoreactivity was detected at all of the KS lesions and in lymphangioma and nonneoplastic lymphatic endothelium. There was no significant relationship between the extent of D2-40 staining and histopathological stage; however, there was a positive correlation between the staining intensity and histopathological stage in KS cases. D2-40 immunoreactivity was detected at all histopathological stages of KS and may be added to the routine immunohistochemical panel used for the differential diagnosis of KS. Widespread D2-40 protein expression is evidence of a lymphatic origin or the differentiation of neoplastic cells in KS, and D2-40 expression increases with tumor progression.

Weiss SW, Goldblum JR (2001) Malignant vascular tumours. In: Weiss SW, Goldblum JR (eds) Enzinger and Weiss’s soft tissue tumors, 4th edn. Mosby, St Louis, pp 917–53

Antman K, Chang Y (2000) Kaposi’s sarcoma. N Engl J Med 342:1027–1038PubMedCrossRef

Pantanowitz L, Grayson W, Simonart T et al (2009) Pathology of Kaposi’s sarcoma. J HIV Ther 14:41–47PubMed

Tapparo JW, Conant MA, Wolfe SF et al (1993) Kaposi’s sarcoma. Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol 28:371–395CrossRef

Ensoli B, Sgadari C, Barillari G et al (2001) Biology of Kaposi’s sarcoma. Eur J Cancer 37:1251–1269PubMedCrossRef

Douglas JL, Gustin JK, Dezube B et al (2007) Kaposi’s sarcoma: a model of both malignancy and chronic inflammation. Panminerva Med 49:119–138PubMed

Noel JC, Hermans P, Andre J et al (1996) Herpesvirus-like DNA sequences and Kaposi’s sarcoma: relationship with epidemiology, clinical spectrum, and histologic features. Cancer 77:2132–2136PubMedCrossRef

Viejo-Borbolla A, Schulz TF (2003) Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV8): key aspects of epidemiology and pathogenesis. AIDS Rev 5:222–229PubMed

Boshoff C, Weiss RA (2001) Epidemiology and pathogenesis of Kaposi’s sarcoma-associated herpesvirus. Philos Trans R Soc Lond B Biol Sci 29:517–534

10.

Beckstead JH, Wood GS, Fletcher V (1985) Evidence for the origin of Kaposi’s sarcoma from lymphatic endothelium. Am J Pathol 119:294–300PubMed

11.

Jones RR, Spaull JS, Spry C et al (1986) Histogenesis of Kaposi’s sarcoma in patients with and without acquired immune deficiency syndrome (AIDS). J Clin Pathol 39:742–749PubMedCrossRef

12.

Karasek MA (1994) Origin of spindle-shaped cells in Kaposi’s sarcoma. Lymphology 27:41–44PubMed

13.

Facchetti F, Lucini L, Gavazzoni R et al (1988) Immunomorphological analysis of the role of blood vessel endothelium in the morphogenesis of cutaneous Kaposi’s sarcoma: a study of 57 cases. Histopathology 12:581–593PubMedCrossRef

14.

Sankey EA, More L, Dhillon AP (1990) QBEnd/10: a new immunostain for the routine diagnosis of Kaposi’s sarcoma. J Pathol 161:267–271PubMedCrossRef

15.

Russell Jones R, Orchard G et al (1995) Immunostaining for CD31 and CD34 in Kaposi sarcoma. J Clin Pathol 48:1011–1016PubMedCrossRef

16.

Hoerl HD, Goldbloom JR (1997) Immunoreactivity patterns of CD31and CD68 in 28 cases of Kaposi’s sarcoma: evidence supporting endothelial differentiation in the spindle cell compartment. Applied Immunohistochemistry 5:173–178CrossRef

17.

Kalof AN, Cooper K (2009) D2–40 immunohistochemistry–so far! Adv Anat Pathol 16:62–64PubMedCrossRef

18.

Jussila L, Valtola R, Partanen TA et al (1998) Lymphatic endothelium and Kaposi’s sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res 58:1599–1604PubMed

19.

Weninger W, Partanen TA, Breiteneder-Geleff S et al (1999) Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi’s sarcoma tumor cells. Lab Invest 79:243–251PubMed

20.

Kahn HJ, Bailey D, Marks A (2002) Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol 15:434–440PubMedCrossRef

21.

Xu H, Edwards JR, Espinosa O et al (2004) Expression of a lymphatic endothelial cell marker in benign and malignant vascular tumors. Hum Pathol 35:857–861PubMedCrossRef

22.

Pyakurel P, Pak F, Mwakigonja AR et al (2006) Lymphatic and vascular origin of Kaposi's sarcoma spindle cells during tumor development. Int J Cancer 119:1262–1267PubMedCrossRef

23.

Dubina M, Goldenberg G (2009) Positive staining of tumor-stage Kaposi sarcoma with lymphatic marker D2-40. J Am Acad Dermatol 61:276–280PubMedCrossRef

24.

Ramírez-Amador V, Martínez-Mata G, González-Ramírez I et al (2009) Clinical, histological, and immunohistochemical findings in oral Kaposi's sarcoma in a series of Mexican AIDS patients. Comparative study. J Oral Pathol Med 38:328–333PubMedCrossRef

25.

Taddeo A, Presicce P, Brambilla L et al (2008) Circulating endothelial progenitor cells are increased in patients with classic Kaposi's sarcoma. J Invest Dermatol 128:2125–2128PubMedCrossRef

26.

Ordóñez NG (2006) Podoplanin: a novel diagnostic immunohistochemical marker. Adv Anat Pathol 13:83–88PubMedCrossRef

27.

Arai E, Kuramochi A, Tsuchida T et al (2006) Usefulness of D2-40 immunohistochemistry for differentiation between Kaposiform hemangioendothelioma and tufted angioma. J Cutan Pathol 33:492–497PubMedCrossRef

28.

Breiteneder-Geleff S, Soleiman A, Kowalski H et al (1999) Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries. Podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154:385–394PubMedCrossRef

29.

Lamovec J, Knuutila S (2002) Kaposi sarcoma. In: Fletcher CDM, Unni KK, Mertens F (eds) World health organisation classification of tumours. Pathology and genetics of tumours of soft tissue and bone. IARC, Lyon, pp 170–172

30.

Fukunaga M (2005) Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumors. Histopathology 46:396–402PubMedCrossRef

31.

Marks A, Sutherland DR, Bailey D et al (1999) Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumors. Br J Cancer 80:569–578PubMedCrossRef

32.

Miettinen M, Lindenmayer AE, Chaubal A (1994) Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Yantigens—evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod Pathol 7:82–90PubMed

33.

Nadimi H, Saatee S, Armin A et al (1988) Expression of endothelial cell markers PAL-E and EN-4 and Ia-antigens in Kaposi's sarcoma. J Oral Pathol 17:416–420PubMedCrossRef

34.

Cheung L, Rockson SG (2005) The lymphatic biology of Kaposi’s sarcoma. Lymphat Res Biol 3:25–35PubMedCrossRef

35.

Carroll PA, Brazeau E, Lagunoff M (2004) Kaposi’s sarcoma-associated herpesvirus infection of blood endothelial cells induces lymphatic differentiation. Virology 328:7–18PubMedCrossRef

36.

Sakakibara S, Tosato G (2009) Regulation of angiogenesis in malignancies associated with Epstein-Barr virus and Kaposi's sarcoma-associated herpes virus. Future Microbiol 4:903–917PubMedCrossRef

37.

Komatsu T, Ballestas ME, Barbera AJ et al (2002) The KSHV latency-associated nuclear antigen: a multifunctional protein. Front Biosci 7:726–730CrossRef

38.

Wang HW, Trotter MW, Lagos D et al (2004) Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 36:687–693PubMedCrossRef

39.

Stürzl M, Brandstetter H, Roth KW (1992) Kaposi’s sarcoma: a review of gene expression and ultrastructure of KS spindle cells in vivo. AIDS Res Hum Retroviruses 8:1753–1762PubMedCrossRef

40.

Hong YK, Foreman K, Shin JW et al (2004) Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet 36:683–685PubMedCrossRef

41.

Marchevsky AM (2008) Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med 132:397–401PubMed

42.

Yu H, Pinkus GS, Hornick JL (2007) Diffuse membranous immunoreactivity for podoplanin (D2-40) distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms. Am J Clin Pathol 128:767–775PubMedCrossRef

43.

Shibahara J, Kashima T, Kikuchi Y et al (2006) Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch 448:493–499PubMedCrossRef

44.

Yu H, Gibson JA, Pinkus GS et al (2007) Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumors. Am J Clin Pathol 128:776–782PubMedCrossRef

45.

Sauter B, Foedinger D, Sterniczky B et al (1998) Immunoelectron microscopic characterization of human dermal lymphatic microvascular endothelial cells. Differential expression of CD31, CD34, and type IV collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma, and hemangioma in situ. J Histochem Cytochem 46:165–176PubMedCrossRef

Title: Lymphatic Differentiation in Classic Kaposi’s Sarcoma: Patterns of D2-40 Immunoexpression in the Course of Tumor Progression
Authors: Nilufer Onak Kandemir
Figen Barut
Banu Dogan Gun
Sevinc Hallac Keser
Nimet Karadayi
Mustafa Gun
Sukru Oguz Ozdamar
Publication date: 01-12-2011
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 4/2011
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-011-9392-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2011

Two Case-Reports of the Limb Salvage Treatment of Osteosarcoma Consolidated with Obvious Pathological Fractures

Breast Tumor Characteristics in Hormone Replacement Therapy Users

High Frequency of Genes’ Promoter Methylation, but Lack of BRAF V600E Mutation among Iranian Colorectal Cancer Patients

Classical and Alternative Nuclear Factor-κB Pathways: A Comparison among Normal Prostate, Benign Prostate Hyperplasia and Prostate Cancer

Down-Regulated miRNA-214 Induces a Cell Cycle G1 Arrest in Gastric Cancer Cells by Up-Regulating the PTEN Protein

Smoking and Polymorphisms in Xenobiotic Metabolism and DNA Repair Genes are Additive Risk Factors Affecting Bladder Cancer in Northern Tunisia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer